Cemiplimab

• Cemiplimab maintenance treatment for advanced adrenocortical cancer Recruiting
  2024-520449-21-00 Phase II 1 country Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
• Randomized phase II trial of Cemiplimab plus OSE2101 (TEDOPI®) as maintenance  therapy in ctDNA positive NSCLC. Recruiting
  2024-519262-42-00 Phase II 1 country Fondazione Ricerca Traslazionale
• Evaluation of efficacy and safety of Cemiplimab as first line treatment for advanced basal cell carcinoma (CEMI-first) - An open label, sing… Recruiting
  2024-517647-31-00 Phase II 1 country Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
• Study of the treatment of patients with non-small cell lung cancer with metastasis with Cemiplimab and subsequent treatment with Cemiplimab … Recruiting
  2024-518812-38-00 Phase II 1 country Fundacion GECP
• Phase II, single arm, multicentre clinical trial to evaluate the activity of encorafenib plus binimetinib followed by Cemiplimab And Fianlim… Recruiting
  2024-513375-40-00 Phase II 1 country Grupo Espanol Multidisciplinar De Melanoma
• First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a ran… Recruiting
  2023-503326-39-00 Phase III 1 country Institut Gustave Roussy
• A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients with Operable No… Recruiting
  2023-509806-31-00 Phase II 3 countries Regeneron Pharmaceuticals Inc.
• LAG3 PET; ImmunoPET imaging with 89Zr-DFO-REGN3767 in patients with advanced solid cancer prior to and during treatment with cemiplimab with… Recruiting
  2024-516795-15-00 Phase II 1 country Universitair Medisch Centrum Groningen
• COMBINATORY IMMUNOTHERAPY-2 (COM-IT-2) A phase 2 randomised open two-arm study to assess the tolerability and efficacy of immunotherapy comb… Recruiting
  2023-510089-28-00 Phase I/II 1 country Oslo University Hospital HF
• A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination … Recruiting
  2023-504845-30-00 Phase I (FiH) 2 countries Grey Wolf Therapeutics Limited
• Immunological variables associated to ICI toxicity in cancer patients Recruiting
  2023-505360-11-00 Phase II 1 country Institut Jules Bordet
• “A phase II, single arm study investigating neoadjuvant plus adjuvant treatment with Cemiplimab in surgically resectable, high risk stage II… Recruiting
  2024-515204-39-00 Phase II 1 country Fondazione Melanoma Onlus
• Study of REGN4018 (Ubamatamab) Administered Alone or in Combination with Cemiplimab in Adult Patients with Recurrent Ovarian Cancer or Other… Recruiting
  2024-510783-23-00 Phase I (FiH) 5 countries Regeneron Pharmaceuticals Inc.
• A study to learn if a combination of Fianlimab and Cemiplimab versus Cemiplimab alone is more effective for adult participants with Advanced… Ended
  2022-501483-18-00 Phase II/III 4 countries Regeneron Pharmaceuticals Inc.
• A trial to find out how safe REGN7075 is and how well it works in combination with cemiplimab for participants with advanced cancers Ended
  2022-501234-37-00 Phase I (FiH) 4 countries Regeneron Pharmaceuticals Inc.
• Tuvusertib (M1774) in Combination with Cemiplimab in Participants with Non-Squamous NSCLC (DDRiver NSCLC 322) Ended
  2022-502010-85-00 Phase I/II 5 countries Merck Healthcare KGaA
• A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com… Ended
  2022-501576-25-00 Phase III 10 countries Regeneron Pharmaceuticals Inc.
• International treatment-extension study in adult participants with multiple myeloma and who have derived clinical benefit from isatuximab Ended
  2023-507180-19-00 Phase II 7 countries Sanofi-Aventis Recherche & Developpement
• Anti-PD-1 re-challenge after immune priming by ipilimumab and immune boosting by radiotherapy in advanced NSCLC. Ended
  2022-500713-79-00 Phase II/III 1 country Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis
• Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U… Ended
  2023-505772-30-00 Phase III 12 countries Regeneron Pharmaceuticals Inc.
• Study comparing the standard administration of immunotherapy (IO) versus the same agent administered each three months in patients with loca… Ended
  2024-513707-14-00 Phase III 1 country Unicancer
• A Phase 1/2, first-in-human, two-part, open-label clinical trial of intravenous administration of CTL-002 given as monotherapy and/or in com… Ended
  2024-512575-12-00 Phase I/II 2 countries CatalYm GmbH
• Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma Ended
  2024-511653-22-00 Phase III 8 countries Regeneron Pharmaceuticals Inc.
• A study to evaluate novel immunotherapy combinations in participants with advanced non-small cell lung cancer (NSCLC) Halted
  2023-508730-34-00 Phase I/II 7 countries Institut De Recherches Internationales Servier IRIS

Showing 25–48 of 56 trials